Medical Device Sector Challenges Draft Bill's Pharma Parallels

India's medical device industry is raising alarms over the draft Drugs, Medical Devices and Cosmetics Bill, 2026, asserting that it inappropriately categorizes medical devices alongside pharmaceuticals. Industry leaders argue that this misclassification could stifle innovation, deter investment, and undermine India's potential as a global hub for medical device manufacturing.

Industry Concerns Over Regulatory Approach

Representatives from the medical device sector, along with healthcare providers and patient safety organizations, have formally opposed the draft bill. They have communicated their concerns to the Union Health Minister, emphasizing that the bill's current form could hinder manufacturing and innovation. According to industry insiders, treating medical devices like pharmaceuticals is scientifically and operationally inappropriate due to the fundamental differences between these two categories.

The draft bill proposes stringent regulatory measures, including criminal penalties for deviations typically handled administratively in other countries. This includes potential imprisonment for labeling and documentation errors, licensing issues, and engineering defects, even when these do not result in harm. Such measures contrast with international norms, where administrative enforcement is the standard practice.

Call for a Distinct Regulatory Framework

Industry associations argue that the draft bill fails to establish a regulatory framework that reflects the unique nature of medical devices. They point out that, globally, medical devices are governed by risk-based conformity assessments, quality management systems, and post-market surveillance. These approaches are favored over punitive measures, which are more common in pharmaceutical regulation.

The draft bill's language, which includes terms such as "adulterated," "spurious," and "misbranded," is seen as drug-centric and not suitable for engineering products like medical devices. Industry leaders stress that aligning medical device regulations with pharmaceutical standards could discourage international investment and innovation, vital for the sector's growth.

Potential Impact on India's Global Aspirations

India has long aspired to become a leading player in the global medical device market, a goal that industry stakeholders fear could be jeopardized by the current draft bill. The associations have urged the government to reconsider the bill's provisions, advocating for a regulatory approach that recognizes the distinct nature of medical devices. They propose a framework that encourages innovation and investment while ensuring patient safety through appropriate compliance measures.

The draft bill is currently under inter-ministerial review, and the medical device sector hopes that their concerns will be addressed in subsequent revisions. As the government seeks to modernize its regulatory framework, industry leaders remain vocal about the need for a balanced approach that supports both growth and safety.